On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

Revolutionary medical treatments offer new hope for chronic pain sufferers through advanced technology, targeted medications ...

Experts with the Cleveland Clinic say the drug has a lot of potential, especially since it is considered nonaddictive.

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx ...

FDA Approves Non-Opioid Treatment for Moderate to Severe Acute Pain as Agency Continues to Take Steps to Support New ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

A common genetic pathway may account for increased risk for atherosclerotic disease in patients with chronic widespread musculoskeletal pain. Chronic widespread pain (CWP) and atherosclerotic disease ...

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...